Sarcopenia and mortality risk in frail older persons aged 80 years and older: results from ilSIRENTE study
Sarcopenia and mortality risk in frail older persons aged 80 years and older: results from ilSIRENTE study
复制标题
DOI：
10.1093/ageing/afs194
复制
发表时间：
2013-03-01
期刊：
影响因子：
6.7
通讯作者：
Onder, Graziano
中科院分区：
文献类型：
--
作者：
Landi, Francesco;Cruz-Jentoft, Alfonso J.;Onder, Graziano
背景和目的：骨骼肌减少症已被认为是老年人身体虚弱和预后不良的可靠标志。我们评估了骨骼肌减少症对生活在社区的体弱老年人全因死亡风险的影响。方法：我们分析了老龄化与长寿研究的数据，这是一项前瞻性队列研究，收集了居住在Sirente地理区域的所有80岁及以上受试者的数据（n=364）。本分析是在基线评估时年龄在80至85岁之间的受试者中进行的（n=197）。主要结局指标为7年随访期间的全因死亡率。根据欧洲老年人肌肉减少症工作组（EWGSOP）的标准，肌肉减少症的诊断需要低肌肉量的记录，以及低肌肉力量或低身体表现的记录。Cox比例回归模型用于估计粗风险比和校正风险比以及因肌肉减少症而死亡的95%置信区间。结果：采用ewgsop建议的标准，共鉴定出43例（21.8%）肌肉减少症患者。在7年的随访中，29名（67.4%）骨骼肌减少症患者死亡，而63名（41.2%）非骨骼肌减少症患者死亡
Background and aims: sarcopenia has been indicated as a reliable marker of frailty and poor prognosis among the oldest individuals. We evaluated the impact of sarcopenia on the risk of all-cause death in a population of frail older persons living in community.Methods: we analysed data from the Aging and Longevity Study, a prospective cohort study that collected data on all subjects aged 80 years and older residing in the Sirente geographic area (n=364). The present analysis was conducted among those subjects who were between 80 and 85 years of age at the time of the baseline assessment (n=197). The main outcome measure was all-cause mortality over 7-year follow-up. According to the European Working Group on Sarcopenia in Older People (EWGSOP) criteria, the diagnosis of sarcopenia required the documentation of low muscle mass and the documentation of either low muscle strength or low physical performance. Cox proportional regression models were used to estimate crude and adjusted hazard ratios and 95% confidence intervals of death by the presence of sarcopenia.Results: using the EWGSOP-suggested criteria, 43 subjects with sarcopenia (21.8%) were identified. During the 7-year follow-up, 29 (67.4%) participants died among subjects with sarcopenia compared with 63 subjects (41.2%) without sarcopenia (P